Von Hippel-Lindau syndrome: Molecular mechanisms of the disease

Clinical and Translational Oncology

Volumn 12, Issue 3, 2010, Pages 160-165

  Calzada, María J ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

HIF ; Prolyl hydroxylase; Renal cell carcinomas; Von Hippel Lindau

Indexed keywords

CYCLIN D1; FIBRONECTIN; GENE PRODUCT; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN JADE 1; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; CARCINOMA CELL; CELL CYCLE ARREST; DRUG TARGETING; EUKARYOTIC FLAGELLUM; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE FUNCTION; HUMAN; HYDROXYLATION; KIDNEY CARCINOMA; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; TIGHT JUNCTION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VON HIPPEL LINDAU DISEASE;

HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77952115959     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0485-9     Document Type: Review

References (90)

1. F. Latif K. Tory J. Gnarra, et al. 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1317 1320 10.1126/science.8493574 8493574 (Pubitemid 23231974)
2. K. Iwai K. Yamanaka T. Kamura, et al. 1999 Identification of the von Hippel-lindau tumorsuppressor protein as part of an active E3 ubiquitin ligase complex Proc Natl Acad Sci U S A 96 12436 12441 10.1073/pnas.96.22.12436 10535940 (Pubitemid 29513520)
3. J. Lisztwan G. Imbert C. Wirbelauer, et al. 1999 The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity Genes Dev 13 1822 1833 10.1101/gad.13.14.1822 10421634 (Pubitemid 29353049)
4. W.G. Kaelin Jr 2002 Molecular basis of the VHL hereditary cancer syndrome Nat Rev Cancer 2 673 682 10.1038/nrc885 12209156 (Pubitemid 37328918)
5. S.O. Ang H. Chen K. Hirota, et al. 2002 Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia Nat Genet 32 614 621 10.1038/ng1019 12415268 (Pubitemid 35435173)
6. M.M. Hickey J.C. Lam N.A. Bezman, et al. 2007 von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis J Clin Invest 117 3879 3889 17992257
7. S.C. Clifford A.H. Prowse N.A. Affara, et al. 1998 Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis Genes Chromosomes Cancer 22 200 209 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-# 9624531 (Pubitemid 28262196)
8. W.Y. Kim W.G. Kaelin 2004 Role of VHL gene mutation in human cancer J Clin Oncol 22 4991 5004 10.1200/JCO.2004.05.061 15611513 (Pubitemid 46646218)
9. E.B. Rankin J.E. Tomaszewski V.H. Haase 2006 Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor Cancer Res 66 2576 2583 10.1158/0008-5472.CAN-05-3241 16510575
10. M. Zimmer D. Doucette N. Siddiqui O. Iliopoulos 2004 Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors Mol Cancer Res 2 89 95 14985465 (Pubitemid 38250425)
11. A. Schoenfeld E.J. Davidowitz R.D. Burk 1998 A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor Proc Natl Acad Sci U S A 95 8817 8822 10.1073/pnas.95.15.8817 9671762 (Pubitemid 28350572)
12. J.R. Gnarra D.R. Duan Y. Weng, et al. 1996 Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma Biochim Biophys Acta 1242 201 210 8603073 (Pubitemid 26106294)
13. C. Blankenship J.G. Naglich J.M. Whaley, et al. 1999 Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity Oncogene 18 1529 1535 10.1038/sj.onc. 1202473 10102622 (Pubitemid 29108052)
14. O. Iliopoulos M. Ohh W.G. Kaelin Jr 1998 pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation Proc Natl Acad Sci U S A 95 11661 11666 10.1073/pnas.95.20.11661 9751722 (Pubitemid 28460471)
15. P.H. Maxwell M.S. Wiesener G.W. Chang, et al. 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 271 275 10.1038/20459 10353251 (Pubitemid 29246458)
16. E.R. Maher W.G. Kaelin Jr 1997 von Hippel-Lindau disease Medicine (Baltimore) 76 381 391 10.1097/00005792-199711000-00001 (Pubitemid 28016534)
17. T. Hsu Y. Adereth N. Kose V. Dammai 2006 Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility J Biol Chem 281 12069 12080 10.1074/jbc.M511621200 16505488 (Pubitemid 43855471)
18. M. Kamada K. Suzuki Y. Kato, et al. 2001 von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility Cancer Res 61 4184 4189 11358843 (Pubitemid 32720988)
19. S. Koochekpour M. Jeffers P.H. Wang, et al. 1999 The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factorinduced invasion and branching morphogenesis in renal carcinoma cells Mol Cell Biol 19 5902 5912 10454537 (Pubitemid 29399295)
20. H.A. Bluyssen M.P. Lolkema M. van Beest, et al. 2004 Fibronectin is a hypoxia-independent target of the tumor suppressor VHL FEBS Lett 556 137 142 10.1016/S0014-5793(03)01392-9 14706840 (Pubitemid 38058569)
21. A. Hergovich J. Lisztwan R. Barry, et al. 2003 Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL Nat Cell Biol 5 64 70 10.1038/ncb899 12510195 (Pubitemid 36054331)
22. M.P. Lolkema D.A. Mans C.M. Snijckers, et al. 2007 The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2 FEBS Lett 581 4571 4576 10.1016/j.febslet.2007.08.050 17825299 (Pubitemid 47418779)
23. M.J. Calzada M.A. Esteban M. Feijoo-Cuaresma, et al. 2006 von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxiainducible factor-independent mechanisms Cancer Res 66 1553 1560 10.1158/0008-5472.CAN-05-3236 16452212 (Pubitemid 43259937)
24. E.J. Davidowitz A.R. Schoenfeld R.D. Burk 2001 VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling Mol Cell Biol 21 865 874 10.1128/MCB.21.3.865-874.2001 11154273 (Pubitemid 32104734)
25. M.A. Esteban M.G. Tran S.K. Harten, et al. 2006 Regulation of E-cadherin expression by VHL and hypoxia-inducible factor Cancer Res 66 3567 3575 10.1158/0008-5472.CAN-05-2670 16585181
26. M.A. Esteban-Barragan P. Avila M. Alvarez-Tejado, et al. 2002 Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions Cancer Res 62 2929 2936 12019174 (Pubitemid 34525781)
27. B. Krishnamachary D. Zagzag H. Nagasawa, et al. 2006 Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B Cancer Res 66 2725 2731 10.1158/0008-5472.CAN-05-3719 16510593
28. M.D. Lewis B.J. Roberts 2003 Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein Oncogene 22 3992 3997 10.1038/sj.onc.1206683 12821933 (Pubitemid 36819639)
29. R.S. Bindra J.R. Vasselli R. Stearman, et al. 2002 VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells Cancer Res 62 3014 3019 12036906 (Pubitemid 34602387)
30. M. Kim Y. Yan K. Lee, et al. 2004 Ectopic expression of von Hippel-Lindau tumor suppressor induces apoptosis in 786-O renal cell carcinoma cells and regresses tumor growth of 786-O cells in nude mouse Biochem Biophys Res Commun 320 945 950 10.1016/j.bbrc.2004.06.042 15240140 (Pubitemid 38887235)
31. J.S. Roe H. Kim S.M. Lee, et al. 2006 p53 stabilization and transactivation by a von Hippel-Lindau protein Mol Cell 22 395 405 10.1016/j.molcel.2006.04.006 16678111
32. H. Yang Y.A. Minamishima Q. Yan, et al. 2007 pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2 Mol Cell 28 15 27 10.1016/j.molcel.2007.09.010 17936701 (Pubitemid 47531976)
33. G. Kurban E. Duplan N. Ramlal, et al. 2007 Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2 Oncogene 27 1004 1213 10.1038/sj.onc.1210709 17700531 (Pubitemid 351225387)
34. M. Ohh R.L. Yauch K.M. Lonergan, et al. 1998 The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol Cell 1 959 968 10.1016/S1097-2765(00)80096-9 9651579 (Pubitemid 128379257)
35. M.A. Esteban S.K. Harten M.G. Tran P.H. Maxwell 2006 Formation of primary cilia in the renal epithelium is regulated by the von hippel-lindau tumor suppressor protein J Am Soc Nephrol 17 1801 1806 10.1681/ASN.2006020181 16775032 (Pubitemid 44036164)
36. R.E. Barry W. Krek 2004 The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis Trends Mol Med 10 466 472 10.1016/j.molmed.2004.07.008 15350900 (Pubitemid 39209214)
37. M.E. Cockman N. Masson D.R. Mole, et al. 2000 Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J Biol Chem 275 25733 25741 10.1074/jbc.M002740200 10823831 (Pubitemid 30658827)
38. K. Tanimoto Y. Makino T. Pereira L. Poellinger 2000 Mechanism of regulation of the hypoxiainducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein EMBO J 19 4298 4309 10.1093/emboj/19.16.4298 10944113 (Pubitemid 30623741)
39. M. Ohh C.W. Park M. Ivan, et al. 2000 Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nat Cell Biol 2 423 427 10.1038/35017054 10878807
40. R.K. Bruick S.L. McKnight 2001 A conserved family of prolyl-4- hydroxylases that modify HIF Science 294 1337 1340 10.1126/science.1066373 11598268 (Pubitemid 33063099)
41. P. Jaakkola D.R. Mole Y.M. Tian, et al. 2001 Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation Science 292 468 472 10.1126/science.1059796 11292861 (Pubitemid 32335942)
42. N. Masson C. Willam P.H. Maxwell, et al. 2001 Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation EMBO J 20 5197 5206 10.1093/emboj/20.18.5197 11566883 (Pubitemid 32910914)
43. G.L. Semenza 2003 Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 721 732 10.1038/nrc1187 13130303
44. K. Kondo J. Klco E. Nakamura, et al. 2002 Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 237 246 10.1016/S1535-6108(02)00043-0 12086860 (Pubitemid 41039148)
45. J.K. Maranchie J.R. Vasselli J. Riss, et al. 2002 The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma Cancer Cell 1 247 255 10.1016/S1535-6108(02)00044-2 12086861 (Pubitemid 41039149)
46. K. Kondo W.Y. Kim M. Lechpammer W.G. Kaelin Jr 2003 Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 E83 10.1371/journal.pbio.0000083 14691554 (Pubitemid 39112142)
47. R.R. Raval K.W. Lau M.G. Tran, et al. 2005 Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma Mol Cell Biol 25 5675 5686 10.1128/MCB.25.13.5675-5686.2005 15964822 (Pubitemid 40853601)
48. S.J. Mandriota K.J. Turner D.R. Davies, et al. 2002 HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron Cancer Cell 1 459 468 10.1016/S1535-6108(02) 00071-5 12124175 (Pubitemid 41039126)
49. S.C. Clifford M.E. Cockman A.C. Smallwood, et al. 2001 Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease Hum Mol Genet 10 1029 1038 10.1093/hmg/10.10.1029 11331613
50. L. Li L. Zhang X. Zhang, et al. 2007 Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations Mol Cell Biol 27 5381 5392 10.1128/MCB.00282-07 17526729 (Pubitemid 47124392)
51. C.J. Hu L.Y. Wang L.A. Chodosh, et al. 2003 Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation Mol Cell Biol 23 9361 9374 10.1128/MCB.23.24.9361-9374.2003 14645546 (Pubitemid 37499822)
52. A.J. Evans R.C. Russell O. Roche, et al. 2007 VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail Mol Cell Biol 27 157 169 10.1128/MCB.00892-06 17060462 (Pubitemid 46013241)
53. S.K. Harten D. Shukla R. Barod, et al. 2009 Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of Ecadherin Mol Biol Cell 20 1089 1101 10.1091/mbc.E08-06-0566 19073886
54. V. Bangiyeva A. Rosenbloom A.E. Alexander, et al. 2009 Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes BMC Cancer 9 229 10.1186/1471-2407-9-229 19602254
55. M.D. Hughes E. Kapllani A.E. Alexander, et al. 2007 HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation Cancer Cell Int 7 13 10.1186/1475-2867-7-13 17598890 (Pubitemid 47086716)
56. V. Singla J.F. Reiter 2006 The primary cilium as the cell's antenna: signaling at a sensory organelle Science 313 629 633 10.1126/science.1124534 16888132 (Pubitemid 44201133)
57. S.M. Nauli J. Zhou 2004 Polycystins and mechanosensation in renal and nodal cilia Bioessays 26 844 856 10.1002/bies.20069 15273987 (Pubitemid 39128099)
58. M.S. Lutz R.D. Burk 2006 Primary cilium formation requires von hippel-lindau gene function in renal-derived cells Cancer Res 66 6903 6907 10.1158/0008-5472.CAN-06-0501 16849532 (Pubitemid 44197663)
59. C.R. Thoma I.J. Frew C.R. Hoerner, et al. 2007 pVHL and GSK3beta are components of a primary cilium-maintenance signalling network Nat Cell Biol 9 588 595 10.1038/ncb1579 17450132 (Pubitemid 46696541)
60. B. Schermer C. Ghenoiu M. Bartram, et al. 2006 The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth J Cell Biol 175 547 554 10.1083/jcb.200605092 17101696 (Pubitemid 44790608)
61. M.P. Lolkema D.A. Mans L.H. Ulfman, et al. 2008 Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor Eur J Hum Genet 16 73 78 10.1038/sj.ejhg.5201930 17912253 (Pubitemid 350269241)
62. H. Yamazaki T. Nakata Y. Okada N. Hirokawa 1995 KIF3A/B: a heterodimeric kinesin superfamily protein that works as a microtubule plus end-directed motor for membrane organelle transport J Cell Biol 130 1387 1399 10.1083/jcb.130.6. 1387 7559760
63. E.W. Kuehn G. Walz T. Benzing 2007 Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development Cancer Res 67 4537 4540 10.1158/0008-5472.CAN-07-0391 17510376 (Pubitemid 46910153)
64. A. Hergovich J. Lisztwan C.R. Thoma, et al. 2006 Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3 Mol Cell Biol 26 5784 5796 10.1128/MCB.00232-06 16847331 (Pubitemid 44134334)
65. G. Kurban V. Hudon E. Duplan, et al. 2006 Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis Cancer Res 66 1313 1319 10.1158/0008-5472.CAN-05-2560 16452184 (Pubitemid 43259909)
66. M. Feijoo-Cuaresma F. Méndez A. Maqueda, et al. 2008 Inadequate activation of the GTPase RhoA contributes to the lack of fibronectin matrix assembly in von Hippel-Lindau protein-defective renal cancer cells J Biol Chem 283 24982 24990 10.1074/jbc.M709390200 18567581
67. A. Grosfeld I.P. Stolze M.E. Cockman, et al. 2007 Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor J Biol Chem 282 13264 13269 10.1074/jbc.M611648200 17339318 (Pubitemid 47100504)
68. N. Tang F. Mack V.H. Haase, et al. 2006 pVHL function is essential for endothelial extracellular matrix deposition Mol Cell Biol 26 2519 2530 10.1128/MCB.26.7.2519-2530.2006 16537898
69. I. Wierzbicka-Patynowski J.E. Schwarzbauer 2003 The ins and outs of fibronectin matrix assembly J Cell Sci 116 3269 3276 10.1242/jcs.00670 12857786 (Pubitemid 37038975)
70. R. Pankov E. Cukierman B.Z. Katz, et al. 2000 Integrin dynamics and matrix assembly: tensindependent translocation of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis J Cell Biol 148 1075 1090 10.1083/jcb.148.5.1075 10704455
71. M.A. Hoffman M. Ohh H. Yang, et al. 2001 von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Hum Mol Genet 10 1019 1027 10.1093/hmg/10.10.1019 11331612 (Pubitemid 32447779)
72. K. Struckmann K. Mertz S. Steu, et al. 2008 pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma J Pathol 214 464 471 10.1002/path.2310 18189328 (Pubitemid 351340566)
73. A. Pause S. Lee K.M. Lonergan R.D. Klausner 1998 The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal Proc Natl Acad Sci U S A 95 993 998 10.1073/pnas.95.3.993 9448273 (Pubitemid 28124900)
74. M. Zatyka N. Fernandes da Silva S.C. Clifford, et al. 2002 Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease Cancer Res 62 3803 3811 12097293 (Pubitemid 34728865)
75. A.R. Schoenfeld T. Parris A. Eisenberger, et al. 2000 The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis Oncogene 19 5851 5857 10.1038/sj.onc.1203985 11127815 (Pubitemid 32005365)
76. M. Kim Y. Katayose Q. Li, et al. 1998 Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 Biochem Biophys Res Commun 253 672 677 10.1006/bbrc.1998.9839 9918786 (Pubitemid 29039201)
77. A.P. Young S. Schlisio Y.A. Minamishima, et al. 2008 VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 Nat Cell Biol 10 361 369 10.1038/ncb1699 18297059 (Pubitemid 351331024)
78. Y. Guo M.C. Schoell R.S. Freeman 2009 The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL) Oncogene 28 1864 1874 10.1038/onc.2009.35 19305426
79. J. An M.B. Rettig 2005 Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity Mol Cell Biol 25 7546 7556 10.1128/MCB.25.17.7546-7556.2005 16107702 (Pubitemid 41170117)
80. H. Qi M. Ohh 2003 The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway Cancer Res 63 7076 7080 14612498 (Pubitemid 37413442)
81. M.I. Zhou H. Wang R.L. Foy, et al. 2004 Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent Cancer Res 64 1278 1286 10.1158/0008-5472.CAN-03-0884 14973063 (Pubitemid 38235594)
82. M.I. Zhou H. Wang J.J. Ross, et al. 2002 The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1 J Biol Chem 277 39887 39898 10.1074/jbc.M205040200 12169691 (Pubitemid 35190975)
83. J.D. Berndt R.T. Moon M.B. Major 2009 Betacatenin gets jaded and von Hippel-Lindau is to blame Trends Biochem Sci 34 101 104 10.1016/j.tibs.2008.12. 002 19217300
84. B. Escudier 2007 Anti-VEGF therapy for renal cell carcinoma Clin Adv Hematol Oncol 5 530 531 17679926 (Pubitemid 47499909)
85. R.J. Motzer B.I. Rini R.M. Bukowski, et al. 2006 Sunitinib in patients with metastatic renal cell carcinoma JAMA 295 2516 2524 10.1001/jama.295.21.2516 16757724 (Pubitemid 43854967)
86. B. Escudier N. Lassau E. Angevin, et al. 2007 Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma Clin Cancer Res 13 1801 1809 10.1158/1078-0432.CCR-06-1432 17363536 (Pubitemid 46952949)
87. C.C. Hudson M. Liu G.G. Chiang, et al. 2002 Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 7004 7014 10.1128/MCB.22.20.7004-7014.2002 12242281
88. G.V. Thomas C. Tran I.K. Mellinghoff, et al. 2006 Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 122 127 10.1038/nm1337 16341243 (Pubitemid 43050086)
89. G. Hudes M. Carducci P. Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 10.1056/NEJMoa066838 17538086 (Pubitemid 46849157)
90. R.J. Motzer B. Escudier S. Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial Lancet 372 449 456 10.1016/S0140-6736(08)61039-9 18653228